Crescent Biopharma (FRA:C68) Dividends Paid

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C68 Crescent Biopharma Inc FRA:C68
18 GF Score
Price €13.80
! 1 Warning Sign
View Full Analysis

What is Crescent Biopharma Dividends Paid?

Dividends Paid only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:C68
18GF Score
Crescent Biopharma Inc FRA:C68
Dividends Paid is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma Business Description

Other Exchanges CBIO:USA
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a clinical-stage biopharmaceutical company based in the United States that develops novel therapeutics for solid tumors. Its lead candidate, CR-001, is a proprietary anti-PD-1/anti-VEGF bispecific antibody designed as a cooperative binding molecule intended to improve on the efficacy and safety profile of standard anti-PD-1 therapies such as pembrolizumab. The company is also advancing CR-002 and CR-003, antibody-drug conjugates directed at validated oncology targets. Crescent's pipeline is focused entirely on immuno-oncology and targeted cancer therapies, with development programs aimed at indications including non-small cell lung cancer and other solid tumors. As a clinical-stage company, it does not yet market approved products and depends on equity financing, partnerships, and licensing arrangements to fund research, clinical trials, and regulatory activities.
18GF Score

Get the complete analysis for FRA:C68

Dividends Paid is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.80
Price